Association of tumor necrosis factor-alpha promoter region gene polymorphism at positions-308G/A,-857C/T, and-863C/A with etanercept response in Iraqi …

S Mohammed, M Zalzala, F Gorial - Archives of Rheumatology, 2022 - pmc.ncbi.nlm.nih.gov
Objectives This study aims to evaluate the association between polymorphisms in the
promoter region of the tumor necrosis factor-alpha (TNF-α) gene at locations-308G/A …

[HTML][HTML] Assessment of medication-related burden among a sample of Iraqi patients with systemic lupus erythematosus and its relationship with disease activity: a …

HK Abbas, DJ Kadhim, FI Gorial, LG Shareef - F1000Research, 2022 - f1000research.com
Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with
high morbidity and disability. The routines involved in taking medications, side effects, the …

[HTML][HTML] Medication-related burden among Iraqi patients with rheumatoid arthritis: An observational study

RK Jwad, DJ Kadhim, MHM Alosami… - …, 2022 - f1000research.com
Background: Rheumatoid arthritis (RA) is a chronically progressing inflammatory disease
having articular, extra-articular, and systemic manifestations of unclear origin. Medication …

Impact of TYMS gene polymorphism on the outcome of methotrexate treatment in a sample of Iraqi rheumatoid arthritis patients–identification of novel single …

QM Mutlak, AA Kasim, AS Aljanabi - Medicine, 2024 - journals.lww.com
The current work aims to evaluate the association between genetic mutations in thymidylate
synthetase (TYMS gene in exon1 and partial regions of promotor and intron 1 [877 bp …

Medication-related burden among Iraqi patients with rheumatoid arthritis: An observational study

R Kadhim Jwad, D Jabbar Kadhim… - …, 2022 - f1000research.com
Background: Rheumatoid arthritis (RA) is a chronically progressing inflammatory disease
having articular, extra-articular, and systemic manifestations of unclear origin. Medication …

[PDF][PDF] Association of the rs1801133 and rs1801131 polymorphisms in the MTHFR gene and the adverse drug reaction of methotrexate treatment in a sample of Iraqi …

QM Mutlak, AA Kasim - Pharmacia (0428-0296), 2024 - pharmacia.pensoft.net
Background: Methotrexate is one of the mainstays for treating rheumatoid arthritis (RA) with
a wide range of adverse drug reactions, however, it's the relationship between adverse drug …

[PDF][PDF] Genetic polymorphism in TNF-α promoter region: its association with severity and susceptibility to rheumatoid arthritis in Iraqi patients with active disease

Z Hashim - Iraqi Journal of Pharmaceutical Sciences, 2023 - iasj.net
To study the prevalence of rs1799964 (-1031 T/C) and rs361525 (-238 G/A) single
nucleotide polymorphisms (SNPs) and their effect on the disease activity, severity, and …

[PDF][PDF] Evaluation of Several Hematologic and Serological Parameters in Rheumatoid Arthritis Patients

ZJ Diwan, WA Al-Marsomy - Ibn AL-Haitham Journal For Pure and Applied …, 2024 - iasj.net
Rheumatoid arthritis (RA) is a chronic inflammatory disease that primarily affects the
synovial joints and produces recurring inflammation of the synovial membrane, which …

Comparison of the effects of Methotrexate and Etanercept on RANKL and OPG as Bone Metabolism Biomarkers in patients with Rheumatoid Arthritis

IO Alshamary, ZM Anwer… - Research Journal of …, 2023 - indianjournals.com
Rheumatoid arthritis is an autoimmune diseasecharacterized by chronic inflammationthat
affects joints and cartilage. Bone complications such asRA-related osteoporosis are one of …

[PDF][PDF] Review of interleukin-6 polymorphisms in rheumatoid arthritis: a genetic implications

DN Alhilali, SI Mohammed, FI Gorial - Journal of Advanced …, 2025 - researchgate.net
The objective review is to inspect the involvement of Interleukin-6 (IL-6) in rheumatoid
arthritis (RA) and to highlight the role of IL-6 and its variants in the pathogenesis of RA and …